ARCHIVES
VOL. 11, ISSUE 1 (2026)
The role of nanotherapeutics in the treatment of Cancer
Authors
Ranjana Chauhan, Abhay Kumar, Sonali Dasgupta, Birjesh Kumar Chaudhary, Pramod Kumar
Abstract
Using the special qualities of nanoparticles
to improve drug delivery and therapeutic efficacy, nanotherapeutics has become
a game-changing method of treating cancer. Conventional cancer treatments, such
as radiation, chemotherapy, and surgery, frequently have drawbacks such
systemic toxicity, non-specific targeting, and drug resistance. These
formulations enhance the delivery of immunotherapeutic and nucleic acids while
enhancing chemotherapeutics' pharmacokinetics and bioavailability. Prominent
FDA-approved nanotherapeutics like Abraxane® and Doxil® serve as examples of
this strategy's clinical effectiveness. Biological barriers that prevent
efficient drug transport, regulatory obstacles that make clinical translation
more difficult, and safety worries about long-term toxicity still pose problems
despite these developments. To overcome current obstacles and fully utilize
nanotechnology in oncology, more research is necessary.
Pages:76-89
How to cite this article:
Ranjana Chauhan, Abhay Kumar, Sonali Dasgupta, Birjesh Kumar Chaudhary, Pramod Kumar "The role of nanotherapeutics in the treatment of Cancer". International Journal of Pharmaceutical Science and Research, Vol 11, Issue 1, 2026, Pages 76-89
Download Author Certificate
Please enter the email address corresponding to this article submission to download your certificate.